We also identified a multifaceted ligand LGALS9 (Supplementary Fig. S12c) binding to diverse receptors, including HAVCR2 (TIM-3) which mediates immune suppression by T cells or macrophages58, immunotherapy checkpoint CD47 that overexpressed in many tumor types59. Here, LGALS9 is linked to neoplasm.